Key Points Interested in Alnylam Pharmaceuticals, Inc.? Here are five stocks we like better. Alnylam set new 2030 goals targeting 25% annual revenue growth and a 30% non-GAAP operating margin, with ...
June 3 () - Alnylam Pharmaceuticals said on Wednesday it has teamed up with artificial-intelligence biotech Inceptive in a deal worth up to $2 billion to use AI to speed up discovery of RNA-based ...
Alnylam Pharmaceuticals' (NASDAQ: ALNY) strong momentum in the first three quarters of 2025 first stalled, then evaporated. Many investors are no doubt looking for a positive catalyst for the stock.
Could Alnylam Pharmaceuticals (NASDAQ:ALNY) become a household name in 2024? At the very least, the company should be well known in the medical community. If you like to wager small amounts of money ...
Zacks Investment Research on MSN
Can Alnylam's broader portfolio ease its dependence on Amvuttra?
Alnylam Pharmaceuticals’ ALNY primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) is preparing to release its quarterly earnings on Thursday, 2026-02-12. Here's a brief overview of what investors should keep in mind before the announcement.
Throughout the last three months, 9 analysts have evaluated Alnylam Pharmaceuticals (NASDAQ:ALNY), offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...
Several positive new analyst notes were the tailwinds pushing the stock of Alnylam Pharmaceuticals (NASDAQ: ALNY) higher on Tuesday. The first day of the holiday-shortened trading week saw Alnylam's ...
Perhaps the best-named TV game show ever, in my opinion, is Who Wants to Be a Millionaire? The show's title is catchy – and gets people thinking about becoming a millionaire. However, planning to win ...
Alnylam Pharmaceuticals (NASDAQ:ALNY), a biotech company specializing in RNA interference therapeutics for genetically defined diseases, has experienced remarkable growth with its stock price surging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results